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Poster Session II 111Conditioning was TBI-based in 80/81 pts and GVHD prophylaxis
was with Cyclosporine and short-course Methotrexate (MTX) (15
mg/m2 d 1 1 and 10 mg/m2 d 1 3, d 1 6 and d 1 11). Fifty of
81 pts received.80% of the planned MTX dose. Forty three pts re-
ceived SCT from a 10/10 high-resolution HLA-matched donor, 25
pts received a 1-antigen mismatched SCT, 12 pts received a 2-anti-
gen mismatched SCT and 1 pt a 3-antigen mismatched SCT. The
donor was male for 68 pts and female for 13 pts. Median CD 34 cell
dose was 7.75  106 (range-9.46  104–33.6  106)/kg. Results:
The estimated 3-year NRM, RR and OAS were 39% (95%CI
25%-50%), 30% (95%CI 17%-41%) and 43% (95%CI 31%-
58%), respectively. In multivariate analysis, CD 34 cell dose
.7.75  106/kg was associated with faster neutrophil engraftment,
p\0.001 and reduced NRM (28% vs. 49%, p5 .019), but did not
influence the incidence of either acute or chronic GVHD or OAS.
On multivariate analysis the most important predictor of reduced
grade 3–4 acute GVHD (22% vs. 49%, p 5 .005), NRM (30 vs.
65%, p5 .006), and improved OAS (50% vs. 24%%) was adminis-
tration of .80% of the planned MTX dose. Conclusion: A higher
CD34 cell dose in unrelated donor SCT does not adversely influ-
ence the incidence of GVHD and is associated with faster neutro-
phil engraftment and a reduction in NRM. Delivery of at least
80% of the planned short-course MTX GVHD prophylaxis con-
tinues to be critical in producing a favourable outcome.299
THE RELATION BETWEEN THE FREQUENCY OF PRESENCE OF THROM-
BOPHILIA AND THROMBOEMBOLIC COMPLICATIONS AFTER ALLOGE-
NEIC HEMATOPOIETIC CELL TRANSPLANTATION (AHCT)
Topcuoglu, P., Gunaltay, S., Dalva, K., Bilgin, A.U., Arat, M.,
Ozcan, M. Ankara University, Ankara, Turkey.
Venous thromboembolism (TE) occurs as a consequence of ge-
netic and environmental factors. Important genetic risk factors are
deficiencies of natural anticoagulants, antithrombin-III (AT-III),
protein C (PC) and PS, and genetic mutations of factor V leiden
(FVL) and prothrombin (PTH A20210). Thrombotic complica-
tions after HCT are usually catheter-related thrombosis (CRT),
pulmonary TE (PTE) and deep vein thrombosis (DVT). Our aim
in this study was to evaluate the effects of the deficiencies of ATIII,
PC and PS, and the gene mutations of FVL and PTH on the inci-
dence of the development of TE complications and liver sinusoidal
obstruction syndrome (SOS) at the early or late period post-HCT.
In our center, pre-transplant work-up includes routine thrombo-
philia tests. Between Apr 1999-Jan 2007 260 patients (M/F: 145/
115, median age: 34 years) admitted to our transplantation center
were retrospectively analyzed for the relation of the presence of
thrombophilia and the frequencies of the occurrence of a TE com-
plications and liver SOS. All but 6 patients (n5 254) underwent al-
logeneic HCT from an HLA identical sibling donor. The ratios of
the detection of the plasma activation level below 50% for PC, PS
and AT-III were 5.8% (12/206), 15.7% (32/204) and 25.4% (66/
260), respectively. Gene mutations were studied in 198 patients
prior to transplant and the frequencies of gene mutations were de-
tected in 11.6% patients (n5 23) either FVL (n5 14) or PTH (n5
9) gene. None of the patients had both mutations, FVL and PTH.
At the peri- or post-transplantation period we observed venous TE
in 24 patients (17 CRT, 2 PE and 5 DVT), liver SOS in 23 patients
and myocard infarction at the early period in only one patient. In 4
out of 12 patients with low PC activity CRT occurred, and liver
SOS was observed in only one patient. In 6 out of 24 patients
with genetic mutation developed a TE complication, 5 CRT and
1 PTE. CRT occurred in 4 of 14 patients with FVL mutation, while
1 CRT and 1 PTE among 9 patients with PTH mutation were ob-
served. Liver SOS was seen in only one patient with PTH heterozy-
gote positive. We found the presence of low PC level or genetic
mutation increased the frequency of the development of TE (OR:
6.9 and 3.7, respectively), but no effect on the liver SOS. In conclu-
sion, the use of thromboprophylaxis at peri-transplant period in pa-
tients with genetic mutations is still a controversial topic; which
should be elucidated with controlled studies.300
ONCE DAILY BUSULFAN CYCLOPHOSPHAMIDE IS WELL TOLERATED
AND EFFECTIVE PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
LeMaistre, J., Bachier, C., Smith, B., LeMaistre, C.F., Shaughnessy, P.J.
Texas Transplant Institute, San Antonio, TX.
Intravenous busulfan (Bu) allowes for the delivery of Bu in one
dose instead of dividing 4 times per day. Pharmacokinetic (PK)
studies of Bu support the feasibility of once daily dosing, and prior
clinical studies found no unexpected toxicity of once daily Bu when
combined with fludarabine. Based on this data we began an institu-
tional protocol of delivering Bu once daily follwed by standard cy-
clophosphamide (CY) and allogeneic hematopoietic stem cell
transplantation (HCT). We report a retrospective review of our in-
stitutional data using once daily BuCY vs 4 daily BuCY and total
body irradiation (TBI)/CY in pts who received allogeneic HCT
from January 2000 to December 2006. Bu 3.2 mg/kg daily  4
days followed by CY 60 mg/kg daily  2 days was given to 42 pa-
tients (pts). Bu 0.8 mg/kg given 4 daily for 4 days followed by
CY 60 mg/kg was given to 15 pts. CY 60 mg/kg daily for 2 days
and fractionated TBI 1200 cGy delivered over 3 days was given to
60 pts. All donors were HLA matched at A, B, C, DR, and DQ
and were related/unrelated in 23/19, 11/4, and 21/39 in the once
daily BuCY, 4 daily BuCY, and TBI/CY, respectively. Signifi-
cantly more pts with myeloid leukemias received a BuCY regimen
and significantly more pts with lymphoid malignancies received
TBI/CY. Median follow up for all pts was 370 days. VOD devel-
oped in 2 pts in the once daily BuCY group, 1 pt in the 4 daily
BuCY group, and in no pts in the TBI/CY group. Acute GVHD
grade II-IV occured in 33% of the once daily BuCY pts, 53% of
the 4 daily BuCY pts, and 32% of the TBI/CY pts. Estimated ac-
tuarial transplant related mortality (TRM) and survival are de-
scribed in the table below. There was no statistical difference in
TRM or survival between the once daily and 4 daily BuCY groups
or the total BuCY group and TBI/CY group. The once daily BuCY
group had significantly less TRM than the TBI/CY group at 100
days (p5 0.04) and at 1 year (p5 0.01). The once daily BuCY group
also had significantly better survival at one year compared to the
TBI/CY group (p 5 0.01), but this became non-significant at 3
years. The significant differences in the pt populations treated in
the BuCY and TBI/CY groups, as well as the retrospective nature
of this study, limit the ability to draw conclusions comparing the
groups. However, this review does demonstrate once daily BuCY
and allogeneic HCT is well tolerated with no unexpected TRM,
and provides good long term survival in pts with myeloid malignan-
cies.Survival and TRM
1  BuCY 4  BuCY CY/TBI
(95%CI) (95%CI) (95%CI)100 day TRM 7% (1–16) 21% (7–51) 22% (15–35)
1 year TRM 21% (11–38) 37% (17–69) 45% (33–59)
1 year Survival 70% (53–82) 47% (21–69) 49% (35–61)
3 year Survival 43% (24–59) 27% (8–50) 37% (24–49)301
THE IMPACT OF THE DISPARITIES OF SHORT TANDEM REPEATS (STR)
BETWEEN DOONOR-RECIPIENT PAIR ON THE ALLOGENEIC HEMATO-
POIETIC CELL TRANSPLANTATION (AHCT) OUTCOME
Serbest, E., Topcuoglu, P., Dalva, K., Bilgin, A.U., Soydan, E.A.,
Ozcan, M., Arslan, O., Ilhan, O., Beksac, M., Gurman, G., Arat, M.
Ankara University, Ankara, Turkey.
STR marker systems are used in the monitoring of hematopoietic
chimerism in patients after AHCST. The biological effect of STR
disparity on AHCT outcome has rarely been studied. Therefore,
we aimed to evaluate the impact of STR disparity on allo-HCT out-
come in our single center. Between Sept 2001 and Feb 2007, 150 pa-
tients (81M/69F, median age: 34 ys) underwent AHCT (Stem cell
